Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 6/20 | 0.66 |
| ▸ | KAT2B | Q92831 | 10/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.40 |
| ▸ | BRD4 | O60885 | 8/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9124850 | 0.87 | BPTF (0.68) | BPTFKAT2BBRD9BRD4NPBWR1 | |
| SCHEMBL9982965 | 0.87 | BPTF (0.68) | BPTFKAT2BBRD9BRD4 | |
| SCHEMBL9123299 | 0.85 | BPTF (0.66) | BPTFKAT2BBRD9BRD4NPBWR1 | |
| SCHEMBL8547853 | 0.74 | BPTF (0.58) | BPTFKAT2BBRD9BRD4ALDH1A1 | |
| SCHEMBL9124983 | 0.71 | BPTF (0.57) | BPTFKAT2BBRD9BRD4NPBWR1 | |
| SCHEMBL9526613 | 0.71 | ADRA1A (0.52) | BPTFBRD9BRD4 | |
| SCHEMBL9529009 | 0.71 | BPTF (0.54) | BPTFKAT2B | |
| SCHEMBL9531508 | 0.70 | DRD2 (0.58) | BPTFBRD9BRD4 | |
| SCHEMBL9527024 | 0.70 | BPTF (0.53) | BPTF | |
| SCHEMBL3254827 | 0.70 | LMNA (0.41) | BPTFALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1417206-B1 | NOVEL 2H-PYRIDAZINE-3-ONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT | EGIS GYOGYSZERGYAR NYRT (HU) | 2010-05-05 | — | — | EP | disclosed |
| US-7098210-B2 | 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient | EGIS Gyógyszergyár Rt. (HU) | 2006-08-29 | — | — | US | disclosed |
| US-20040171619-A1 | Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient | EGIS GYOGYSZERGYAR RT. (HU) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171619-A1 | Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient | HTR2C, HTR5A, HTR3C | BPTF 3074/4885KAT2B 3579/4885BRD9 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.